REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
310.83
+4.20 (+1.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close306.63
Open306.34
Bid0.00 x 800
Ask0.00 x 900
Day's Range303.77 - 311.90
52 Week Range295.27 - 442.00
Volume842,945
Avg. Volume823,300
Market Cap33.932B
Beta (3Y Monthly)1.05
PE Ratio (TTM)14.72
EPS (TTM)21.11
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est392.00
Trade prices are not sourced from all markets
  • This would be the worst-case scenario for health companies, according to UBS
    MarketWatch12 minutes ago

    This would be the worst-case scenario for health companies, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for certain health companies.

  • Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
    Zacks22 hours ago

    Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Alnylam Completes Enrollment in Phase III Study of Lumasiran
    Zacks2 days ago

    Alnylam Completes Enrollment in Phase III Study of Lumasiran

    Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

  • Barrons.com2 days ago

    Regeneron Stock Faces More Uncertainty as Rivals Gear Up, Analyst Says

    Most of the biotech’s revenue comes from a single blockbuster drug, called Eylea. And Eylea is under siege.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold REGN had net inflows of $1.82 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Reuters2 days ago

    CORRECTED-UPDATE 1-Uganda clears three experimental Ebola treatments, watches for spread

    Health workers have got the all-clear to use three experimental Ebola treatments in Uganda, a week after the deadly disease spread over the border from Democratic Republic of Congo, authorities said on Tuesday. Two people who had travelled from Congo died in Uganda last week, the World Health Organization said. A three-year-old boy who was sent back to Congo after testing positive for the disease died at the weekend, Congo's health ministry said.

  • Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
    Zacks3 days ago

    Regeneron (REGN) Presents Positive Data on Lymphoma Candidate

    Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.

  • TheStreet.com4 days ago

    2 Well-Known Stocks You Should Consider Shorting This Week

    Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)
    Insider Monkey6 days ago

    Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • PR Newswire6 days ago

    Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early-stage data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The emerging data, which includes patients with R/R diffuse large B-cell lymphoma (DLBCL) who had progressed after CAR-T therapy, will be presented tomorrow at the 24th Congress of the European Hematology Association (EHA). "We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, M.D., Ph.D., Senior Vice President and Head of Clinical and Translational Sciences, Oncology at Regeneron.

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling
    Simply Wall St.8 days ago

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Barrons.com9 days ago

    The Regeneron Stock Selloff Is Driven by Fear, Not Substance, Analyst Says

    Regeneron (ticker: REGN) markets drugs for a range of conditions, including rheumatoid arthritis and various forms of cancer, and shares have struggled since last fall. Regeneron stock is among the worst-performing of the large biotech companies. In May, the company announced earnings that fell short of analyst expectations, as Barron’s reported.

  • Here's Why Regeneron Pharmaceuticals Tumbled 12% in May
    Motley Fool10 days ago

    Here's Why Regeneron Pharmaceuticals Tumbled 12% in May

    Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.

  • MoneyShow10 days ago

    Regeneron- A Rich Research Pipeline

    Regeneron Pharmaceuticals (REGN) recently had a rough earnings release; the biotech firm reported first-quarter revenue of $1.71 billion, a 13% year-over-year jump but about $50 million lower than analysts' expectation, asserts Scott Chan, editor of The Complete Investor.

  • Benzinga12 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

    Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zacks14 days ago

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

  • Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?
    Zacks14 days ago

    Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?

    Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
    Zacks15 days ago

    Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

    GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

  • Reuters16 days ago

    Sanofi loses German patent case against Amgen over cholesterol drug

    Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.

  • Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
    American City Business Journals20 days ago

    Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

    Cambridge-based Epizyme is now awaiting FDA for approval for its epigenetics first product, tazemetostat, with plans to quickly expand its applications.

  • Save the Date: 11 Biotech Stocks to Put on Your Radar
    Kiplinger21 days ago

    Save the Date: 11 Biotech Stocks to Put on Your Radar

    This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of

  • Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
    Zacks22 days ago

    Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate

    Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.

  • Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
    Zacks28 days ago

    Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service

    Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service

  • PR Newswire28 days ago

    Regeneron Announces Upcoming Investor Conference Presentation

    TARRYTOWN, N.Y., May 23, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the Goldman Sachs 40 th Annual Global Healthcare Conference at 9:20 a.m. Pacific ...